J.M. Forbes & Co’s Biogen BIIB Stock Holding History

J.M. Forbes & Co’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$404K	Hold	1,869	–	–	0.03%	121
2026 Q1	$343K	Hold	1,869	–	–	0.03%	119
2025 Q4	$329K	Hold	1,869	–	–	0.03%	117
2025 Q3	$262K	Hold	1,869	–	–	0.02%	130
2025 Q2	$235K	Hold	1,869	–	–	0.02%	135
2025 Q1	$256K	Hold	1,869	–	–	0.02%	131
2024 Q4	$286K	Hold	1,869	–	–	0.03%	128
2024 Q3	$362K	Hold	1,869	–	–	0.04%	114
2024 Q2	$433K	Hold	1,869	–	–	0.04%	102
2024 Q1	$403K	Sell	1,869 -39	-2%	-$9.13K	0.04%	103
2023 Q4	$494K	Hold	1,908	–	–	0.06%	97
2023 Q3	$490K	Sell	1,908 -170	-8%	-$45.5K	0.06%	92
2023 Q2	$592K	Hold	2,078	–	–	0.07%	89
2023 Q1	$578K	Sell	2,078 -21	-1%	-$5.81K	0.08%	68
2022 Q4	$581K	Hold	2,099	–	–	0.08%	67
2022 Q3	$560K	Buy	2,099 +55	+3%	+$11.7K	0.09%	70
2022 Q2	$417K	Hold	2,044	–	–	0.06%	82
2022 Q1	$430K	Sell	2,044 -40	-2%	-$8.7K	0.05%	86
2021 Q4	$500K	Hold	2,084	–	–	0.06%	84
2021 Q3	$590K	Sell	2,084 -32	-2%	-$10.5K	0.07%	72
2021 Q2	$733K	Sell	2,116 -5	-0.2%	-$1.51K	0.09%	65
2021 Q1	$593K	Sell	2,121 -10	-0.5%	-$2.7K	0.08%	67
2020 Q4	$522K	Sell	2,131 -20	-0.9%	-$5.16K	0.08%	69
2020 Q3	$610K	Hold	2,151	–	–	0.1%	61
2020 Q2	$575K	Hold	2,151	–	–	0.1%	59
2020 Q1	$681K	Sell	2,151 -858	-29%	-$260K	0.15%	48
2019 Q4	$893K	Hold	3,009	–	–	0.15%	58
2019 Q3	$701K	Hold	3,009	–	–	0.13%	62
2019 Q2	$704K	Hold	3,009	–	–	0.14%	59
2019 Q1	$711K	Hold	3,009	–	–	0.15%	57
2018 Q4	$905K	Hold	3,009	–	–	0.21%	53
2018 Q3	$1.06M	Sell	3,009 -10	-0.3%	-$3.44K	0.23%	55
2018 Q2	$876K	Hold	3,019	–	–	0.2%	57
2018 Q1	$827K	Sell	3,019 -110	-4%	-$34.1K	0.19%	58
2017 Q4	$997K	Buy	3,129 +8	+0.3%	+$2.57K	0.23%	56
2017 Q3	$977K	Hold	3,121	–	–	0.24%	51
2017 Q2	$846K	Buy	3,121 +19	+0.6%	+$5.02K	0.22%	52
2017 Q1	$848K	Hold	3,102	–	–	0.22%	53
2016 Q4	$879K	Buy	3,102 +1	+0%	+$296	0.24%	50
2016 Q3	$971K	Hold	3,101	–	–	0.27%	51
2016 Q2	$749K	Hold	3,101	–	–	0.21%	51
2016 Q1	$807K	Hold	3,101	–	–	0.23%	49
2015 Q4	$949K	Hold	3,101	–	–	0.25%	48
2015 Q3	$904K	Hold	3,101	–	–	0.26%	48
2015 Q2	$1.25M	Sell	3,101 -132	-4%	-$53K	0.34%	46
2015 Q1	$1.36M	Hold	3,233	–	–	0.36%	47
2014 Q4	$1.28M	Hold	3,233	–	–	0.33%	45
2014 Q3	$1.07M	Hold	3,233	–	–	0.27%	50
2014 Q2	$1.02M	Hold	3,233	–	–	0.25%	50
2014 Q1	$988K	Hold	3,233	–	–	0.26%	51
2013 Q4	$903K	Hold	3,233	–	–	0.23%	55
2013 Q3	$778K	Sell	3,233 -250	-7%	-$56K	0.22%	56
2013 Q2	$750K	Buy	+3,483	New	+$744K	0.22%	54

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

J.M. Forbes & Co's BIIB Position: Q2 2026 in Review

J.M. Forbes & Co held its Biogen (BIIB) position steady in Q2 2026 at 1,869 shares worth $404K. The position accounts for 0.03% of the portfolio, ranked #121.

J.M. Forbes & Co first reported a position in BIIB in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.36M in Q1 2015. 1,038 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

J.M. Forbes & Co held 1,869 shares of Biogen worth $404K as of Q2 2026.
J.M. Forbes & Co left its Biogen share count unchanged in Q2 2026.
Biogen made up 0.03% of J.M. Forbes & Co's portfolio in Q2 2026, its #121 holding.
J.M. Forbes & Co first reported a position in Biogen in Q2 2013 and has held it in 53 quarters since.
J.M. Forbes & Co's Biogen position peaked at $1.36M in Q1 2015.
1,038 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on J.M. Forbes & Co's 13F filing for Q2 2026, filed 20 Jul 2026.